Premium
Skin homograft survival in cancer chemotherapy patients
Author(s) -
Gorgun Bedrettin,
Watne Alvin L.
Publication year - 1966
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196609)19:9<1316::aid-cncr2820190921>3.0.co;2-y
Subject(s) - medicine , folinic acid , methotrexate , mitomycin c , chemotherapy , drug , toxicity , cancer chemotherapy , oncology , surgery , pharmacology , fluorouracil
The immunosuppressive activity of various anticancer drugs has been evaluated by its effect on skin homograft survival in 45 patients. Patients with no evident advanced malignant disease and cancer patients receiving no therapy showed a mean skin homograft survival time of 8 days. Among the various types of anticancer therapy utilized, the drugs AB 132, hydroxyurea, mitomycin C and methotrexate with folinic acid each gave a significant prolongation of skin homograft survival. Neither the degree of drug toxicity nor difference in blood type or sex significantly altered the skin homograft survival under this study.